• Long-term extension of the Phase 2 VISIONARY-MS clinical trial of CNM-Au8 exhibited significant evidence of repair and remyelination across multiple paraclinical endpoints (change from original baseline, p < 0.05)
• Significantly enhanced clinical outcomes were associated with long-term daily oral CNM-Au8(R) 30 mg treatment (change from original baseline; p < 0.05)
• Long-term administration of CNM-Au8, spanning up to three years, was well-tolerated, with no significant safety concerns identified
• This marks the first Phase 2 clinical trial in MS utilizing a non-immunomodulatory drug to achieve a clinical outcome demonstrating improved function supporting remyelination and reparative effects

Clene (NASDAQ: CLNN), along with its subsidies, “Clene”, and its wholly owned subsidiary Clene Nanomedicine, Inc., a pioneering clinical-stage biopharmaceutical firm dedicated to enhancing mitochondrial health and safeguarding neuronal function to combat neurodegenerative disorders such as amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”), unveiled the comprehensive findings of the Phase 2 VISIONARY-MS long term extension (“LTE”) study at the esteemed 2024 American Academy of Neurology (“AAN”) Annual Meeting in Denver (https://ibn.fm/Ro9gg).

During the Emerging Science Session, Dr. Michael Barnett, MBBS, FRACP, FRCP, PhD, representing the University of Sydney, presented compelling data showcasing the sustained clinical, functional, and structural enhancements correlated with the daily oral administration of CNM-Au8(R) 30 mg for a remarkable period of up to three years.

These groundbreaking long-term outcomes from the Phase 2 VISIONARY-MS clinical trial underscored the compelling evidence endorsing the reparative and remyelinating effects of CNM-Au8 treatment. The extended findings build upon the trial’s earlier outcomes from the double-blind phase, which exhibited noteworthy improvements in low contrast letter acuity and the modified MS Functional Rating Scale, serving as the primary and secondary endpoints of the study, with continued enhancements noted during the LTE.

The significant and consistent results observed across a spectrum of paraclinical exploratory endpoints further reinforce the sustained clinical advantages experienced by study participants across various clinical outcome measures, aligning with the consistent enhancements in neuronal function and remyelination.

Key highlights from the “Phase 2 CNM-Au8 VISIONARY-MS Trial: Long-Term Extension Results” presentation include:

1. Enhanced Cognition and Vision

• Individuals originally assigned to CNM-Au8 treatment demonstrated continued substantial enhancement in vision, evidenced by significant improvements in low contrast letter acuity. More than half of the participants exhibited improvements of 10 or more letters on a low-contrast Sloan eye chart, with some achieving increases of up to 38 letters (vs. original baseline, p < 0.001 via mixed model repeat measures analysis, or MMRM).
• Participants initially assigned to placebo, subsequently transitioning to CNM-Au8 following the 48-week double-blind period, also experienced noteworthy improvement in vision, as demonstrated by low contrast letter acuity after receiving treatment with CNM-Au8 30 mg (vs. original baseline, p < 0.05 via MMRM).
• Subjects treated with CNM-Au8 demonstrated significant enhancements of up to 29 points (max score =110) in cognition and working memory as measured by the Symbol Digit Modality Test (“SDMT”) (vs. original baseline, p < 0.001 via MMRM).

2. Physiologic Evidence of Repair and Remyelination

• Participants receiving CNM-Au8 treatment showcased substantial improvements in both amplitude (vs. original baseline, p < 0.01 via MMRM) and latency (vs. original baseline, p = 0.06 via MMRM) as measured by multi-focal visual evoked potentials, serving as physiological indicators of signal strength and speed along the visual pathway, indicative of neuronal health and remyelination, respectively.

3. Structural Evidence of Repair and Remyelination:

• MRI evaluations of axial diffusivity exhibited significant enhancements in T2 brain lesions among study participants treated with CNM-Au8 (vs. original baseline, p < 0.05 via MMRM).
• MRI assessments of T2 lesion myelin water fraction (“MWF”) and magnetization transfer ratio (“MTR”), both indicative of remyelination, demonstrated improvements following long-term CNM-Au8 treatment (MWF: vs. original baseline, p < 0.05 via MMRM; MTR: vs. original baseline, p = 0.06 via MMRM).

CNM-Au8 exhibited excellent tolerability, with no significant safety concerns identified.

“Observing such a profound clinical benefit with corresponding improvements in physiologic measures utilizing a mechanism that does not target immune system modulation has never been demonstrated in prior multiple sclerosis trials,” said Dr. Benjamin Greenberg, Head of Medicine for Clene. “This is a very exciting data set that gives hope to the millions of people who are suffering from this disabling disease.”

The presentation is available on the company’s website at https://ibn.fm/06tSN.

For more information, visit the company’s website at www.Clene.com.

NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN

• Fr8Tech, a tech company on a mission to revolutionize cross-border shipping, just posted 30% year-over-year (“YOY”) revenue growth and a 278% YOY growth in Fr8Fleet volume for Q1 2024
• This growth was attributed to the addition of the Fr8Fleet offering in 2022, which sought to address specific customer needs
• The company looks to build on this success by fostering even stronger relationships with existing customers and adding new customers to its network
• Its management believes that this approach will be integral in realizing its $25-$30 million annual revenue projection for the 2024 financial year

Freight Technologies (NASDAQ: FRGT) (“Fr8Tech”), a tech company on a mission to revolutionize cross-border shipping by offering carriers and shippers flexibility, visibility, and simplicity, just released preliminary financial results for the first quarter of the 2024 financial year (“Q1 2024”). Of note was the 30% revenue growth over the same period in the previous year, totaling $4.3 million. The company also reported a 25% growth in volume for Fr8Fleet from the fourth quarter of the 2023 fiscal year and a 278% year-over-year growth with approximately 3,400 completed shipments (https://ibn.fm/ir97f).

According to the company’s management, this growth and impressive performance was primarily attributed to adding the Fr8Fleet offering, which sought to address specific customer pain points by securing dedicated carrier capacity and providing responsive, high-quality customer service.

“The company’s addition of its Fr8Fleeet offering in 2022 was the right strategic response to the market dynamics of the Mexican domestic Over the Road (“OTR”) freight industry,” noted Don Quinby, Fr8Tech’s Chief Financial Officer (“CFO”).

“It has proven to be a highly valued service for large enterprise customers and is a key differentiator for Fr8Tech,” he added.

Fr8Tech looks to build even stronger relationships with its new and existing customers. Additionally, it is committed to bolstering its carrier capacity while improving its platform’s capabilities and efficiency, which has been a game-changer in the industry. According to its CEO and Director, Javier Selgas, focusing on these aspects will allow the company to realize its 2024 annual revenue projections of between $25 and $30 million.

“Underlying economic activity in both Mexico and the US, coupled with ongoing near-shoring activity of US and foreign multinational companies, suggests continued growing demand for domestic and cross-border freight services,” noted Mr. Selgas.

“We are well positioned to take advantage of this market opportunity, and the Fr8Tech team continues to innovate to make market share gains over the coming year,” he concluded.

If recent events in the region are anything to go by, Fr8Tech anticipates a significant uptick in the demand for its products and services. Earlier in the year, railroad disruptions, owing to a surge in smuggling of migrants through Mexico, saw nearly 10,000 rail cars stranded on both sides of the border (https://ibn.fm/wch92). Such events have forced companies to explore more reliable options, and Fr8Tech offers just that and more. With its market positioning, distinctive freight matching capabilities and easy-to-use features of its platform, the company is confident that it will bring plenty of industry participants together through Fr8App to meet its revenue projections for the year.

For more information, visit the company’s website at www.Fr8Technologies.com and its freight matching platform information site at www.Fr8.App.

NOTE TO INVESTORS: The latest news and updates relating to FRGT are available in the company’s newsroom at https://ibn.fm/FRGT

Corporate Communications
IBN (InvestorBrandNetwork)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com

• SUIC recently announced that I.Hart Group Taiwan and MONGA(C) Fried Chicken had signed franchise authorizations in Japan and China
• The franchise authorizations are expected to grow the number of stores operated by I.Hart Group to 200 outlets in 2024 and more than 500 stores over the next five years
• The authorizations covering Shandong Province in China will see the Shandong Authorized company opening ten stores during the first year and 300 stores within the subsequent five years. Japan is another authorization which will target the greater Tokyo metropolitan area
• The new authorizations are part of SUIC’s commitment to grow its footprint in the global food market and serve more customers around the world

SUIC Worldwide Holdings (OTC: SUIC) is a company helping build tech-enabled businesses of the future by providing research and development and venture financing as well as investing in enterprises that develop products and services adopting core capabilities of the Internet of Things, cloud computing, mobile payment, big data, blockchain, and artificial intelligence. SUIC is the biggest investor, shareholder, and major operating partner of Beneway USA, a company whose wholly owned subsidiary, I.Hart Group Taiwan, is making strides in the global food industry.

I.Hart Group currently operates 150 global franchised locations in different countries under various brands and products, including MONGA(C) Taiwan-style Fried Chicken, flower tea drinks, dumplings, cloud kitchen management, AI smart machines, and more. As of February 2024, I.Hart Group had a total of 90 MONGA(C) Fried Chicken stores and outlets in 10 countries (https://ibn.fm/j1bJ4), but this number is set to grow following recent developments.

SUIC recently announced that I.Hart Group and MONGA(C) Fried Chicken had signed franchise authorizations in Japan and China, which are expected to expand significantly the presence of both companies by growing the number of I.Hart Group’s MONGA(C) Fried Chicken outlets initially to 95, across 11 countries (https://ibn.fm/6Fqe5).

The authorizations in China cover 16 cities across Shandong, China’s second-largest province, with a population of more than 100 million. According to SUIC, the Shandong Authorized company has committed to opening ten stores during the first year and 300 stores within the subsequent five years. To make this ambitious goal a reality, I.Hart Group and the Shandong Authorized company, in conjunction with at least 50 or more franchise owners every year, will work together to operate MONGA(C) Fried Chicken stores in various locations within the province.

Additionally, the signed franchise authorizations in Japan cover the expansive city of Tokyo and its surrounding satellite cities, home to more than 38 million people. The authorizations aim to tap into the region’s status as the world’s largest metropolitan area, representing a potentially large market for the stores. Moreover, the Greater Tokyo metropolitan area’s GDP is second only to the New York metropolitan area, signaling the health of the city’s economy and, by extension, the ability of its populace to buy consumer goods like the food offered at the MONGA(C) Fried Chicken outlets.

“We dedicate our team and resources to the success and expansion of our franchise development efforts and global transformation journey. We will continue to increase this momentum in 2024 and find opportunities in serving more customers around the world, growing our footprint in the global food market by tenfold,” commented Hank Wang, SUIC CEO.

According to the company, the new franchise authorizations will lead to the opening of new franchises, increasing the number of stores operated by I.Hart Group to 200 outlets in 2024 and more than 500 stores over the next five years.

For more information, visit the company’s website at www.SinoUnitedCo.com.

NOTE TO INVESTORS: The latest news and updates relating to SUIC are available in the company’s newsroom at https://ibn.fm/SUIC

• Industrial and commercial buildings are responsible for a significant amount of the carbon emissions affecting the planet’s climate, according to pollution experts
• Correlate Energy Corp. is a distributed energy solutions company, focusing on the North American market, that is dedicated to helping client companies improve their energy use profiles, reducing emissions while maintaining their budgets
• Correlate is strategically positioned to leverage government financial incentives on its clients’ behalf, as well as offering an array of modern, targeted tools to achieve data-driven solutions
• The company currently has about $150 million of in-progress projects in various stages of development

The drive to reduce carbon emissions and improve energy use efficiency for corporate and government office buildings is increasingly driving strategy sessions on climate change, amid efforts to meet the goals of the past decade’s UN-brokered Paris Agreement to battle carbon-based pollution worldwide.

In the European Union, where the ruling council announced earlier this month that it has formally adopted the more stringent climate plan regulations of its Energy Performance of Buildings Directive (https://ibn.fm/J9o8q), buildings account for about 40 percent of the league of states’ energy consumption, with more than half of its gas consumption and 35 percent of the energy-related greenhouse gas emissions (https://ibn.fm/PTg0O).

Distributed energy solutions company Correlate Energy (OTCQB: CIPI) is welcoming the international attention on industrial and commercial building energy use. The company has demonstrated the ability to create stockholder value while facilitating this building utility trend, offering to finance, develop, and profitably sell localized clean energy solutions and microgrids to industrial, commercial, and residential customers.

Correlate’s focus is on the North American market, working with government incentives and other financial opportunities to help clients find an affordable way to step up their energy use infrastructure.

“We have this constant conveyor belt of a maturity of opportunities (that) really allows us to smartly invest in different parts of the business from origination of sales to construction and oversight,” Correlate Energy President and CEO Todd Michaels told Proactive Investors (https://ibn.fm/8MA23). “Solar’s the most applicable technology. Right now it’s basically beating the grid for costs … so that’s the lead horse. In behind that comes things like batteries, where if somebody wants to have resiliency — let’s say the grid goes down in Texas or California or the Northeast, which is very prevalent nowadays — things like storage can allow them to have 24 / 7 uninterrupted operations.”

By leveraging opportunities with clients that have dozens of locations across the country, Correlate is providing retrofit upgrades at a number of sites, while positioning itself to scale up by retaining ownership of some of its energy systems and acquiring promising renewable energy companies.

The company currently has about $150 million worth of projects being completed, according to its officers.

Correlate announced a partnership with Carbonsight (by Autocase) in February that is strengthening its ability to take a data-driven approach to its decarbonization planning process. The Carbonsight software makes it easier for building portfolio managers to quantify costs, savings and timelines for putting their targeted energy projects into motion (https://ibn.fm/tqvTV).

The company is also utilizing Xendee’s distributed energy resource platform as a tool to effectively complete the site analysis process and design proposals for projects, Chief Product Officer Leif Elgethun said in a recent webinar.

With cutting-edge tools and financing options that were unknown just a few years ago, the company is becoming a significant partner in the worldwide effort to reduce carbon emissions.

For more information, visit the company’s website at www.Correlate.Energy, including the following:

Breaking Down Barriers To Your ESG Goals While Generating Additional Net Operating Income: www.Correlate.Energy/our-process
Platform Generates New Rent And Operating Income, Allowing You To Meet Your ESG Goals: www.Correlate.Energy/program

NOTE TO INVESTORS: The latest news and updates relating to CIPI are available in the company’s newsroom at https://ibn.fm/CIPI

• PCPs play pivotal role in successful healthcare approach
• Evidence shows that primary care helps prevent illness and death
• Astiva Health has established a healthcare ecosystem where best PCPs are rewarded for expertise, commitment

The importance of primary care in a successful healthcare approach has been clearly shown through decades of research. Astiva Health is dedicated to enhancing the quality of medical care through a strong doctor-patient relationship with the success of its model hinging on knowledgeable, competent, and hard-working primary care physicians (“PCPs”) who play a pivotal role in the healthcare system.

“Evidence of the health-promoting influence of primary care has been accumulating ever since researchers have been able to distinguish primary care from other aspects of the health services delivery system,” states a National Library of Medicine research report (https://ibn.fm/aRCQx). “This evidence shows that primary care helps prevent illness and death, regardless of whether the care is characterized by supply of primary care physicians, a relationship with a source of primary care, or the receipt of important features of primary care. The evidence also shows that primary care (in contrast to specialty care) is associated with a more equitable distribution of health in populations, a finding that holds in both cross-national and within-national studies.”

With this in mind, Astiva Health is dedicated to establishing a healthcare ecosystem where the best primary care doctors are not only rewarded for their expertise but also for their commitment to providing the best possible care. Astiva Health advocates for a physician-led approach that motivates primary care physicians to provide exceptional care. By offering incentives for doctors who show remarkable dedication and achieve excellent patient outcomes, Astiva emphasizes its commitment to a model that financially rewards PCPs for their outstanding performance.

In addition, Astiva Health collaborates with more than 60 physician groups with a focus on empowering PCPs to excel by allowing them more time for patient interactions through the strategic use of technology. This not only enhances the quality of consultations but also integrates care by providing real-time access to health data. This system ensures seamless communication with government health systems, further improving the efficacy of healthcare delivery.

The company is also dedicated to simplifying processes for doctors, achieving an impressive approval rate for requests and significantly reducing review times. Astiva Health’s streamlined approach includes an optimized annual wellness visit form, now condensed to only three pages. This concise form is designed to be filled out efficiently by physicians and their staff, saving valuable time and allowing them to focus more on patient care rather than paperwork. Together with the conversion of the form from paper to electronic format and a new hosting system, patients’ health data now can be transferred from providers’ office to Astiva accurately in real time. This initiative is part of the company’s commitment to enhancing operational efficiency and supporting healthcare providers in delivering top-notch care efficiently.

Finally, Astiva Health actively works with its patients to facilitate more frequent doctor visits, supporting a model that rewards physicians for top-tier primary care services. By aligning incentives and employing a unified system for doctor-patient interactions, Astiva Health fosters a proactive environment where primary care thrives, ultimately benefiting the overall health and well-being of their patients.

PCPs are recognized as the gatekeepers to specialists, often determining the frequency of patient visits and overseeing comprehensive care management. Astiva Health’s holistic approach underscores the company’s understanding that effective primary care is foundational, requiring a unique blend of expertise and dedication to maintain stability and control within the healthcare system.

Astiva Health advocates for a healthcare ecosystem where the best doctors are not only rewarded for their expertise but also for their commitment to providing the best possible care. This model naturally encourages preventative primary care, a cornerstone of Astiva’s philosophy, highlighting how preventive measures are not only beneficial for health but also significantly more cost-effective than reactive care following emergency situations.

For more information, visit the company’s website at www.AstivaHealth.com.

NOTE TO INVESTORS: The latest news and updates relating to Astiva Health are available in the company’s newsroom at https://ibn.fm/Astiva

BioLargo (OTCQB: BLGO), a pioneering cleantech and life sciences company, has made significant strides with its Aqueous Electrostatic Concentrator (“AEC”) technology, setting a new benchmark in the water treatment industry. This innovative technology has proven to effectively remove per- and polyfluoroalkyl substances (“PFAS”) from water, surpassing the stringent new U.S. Environmental Protection Agency (“EPA”) drinking water standards for PFAS chemicals set to take effect on April 10, 2024. The AEC technology’s ability to generate significantly less PFAS-laden solid waste compared to traditional methods like carbon filtration or ion exchange positions it as a potentially more sustainable and cost-effective solution for water providers.

The importance of BioLargo’s breakthrough cannot be overstated, especially in light of the EPA’s newly finalized regulations that aim to limit PFAS in public drinking water to nearly undetectable levels, as low as 4 parts per trillion. PFAS chemicals, which are used in various consumer goods and industrial applications, have been linked to serious health issues, including cancer and developmental problems. Traditional water treatment technologies often fall short in efficiently removing certain PFAS compounds and tend to produce large volumes of hazardous waste. In contrast, BioLargo’s AEC technology not only meets but exceeds these new EPA standards for all PFAS contaminants, offering a more sustainable and cost-effective solution for water providers.

The company’s commitment to addressing the challenges posed by PFAS contamination extends beyond the development of its AEC technology. BioLargo also provides advisory services, analytical testing, and education on PFAS science and regulations to assist water providers in navigating the complexities of compliance with the new rules. This comprehensive approach underscores BioLargo’s dedication to supporting its customers through innovative technology and expert guidance.

The financial implications of BioLargo’s technological advancements are also noteworthy. The company’s stock price saw an increase of approximately 4.93% to $0.35, reflecting investor confidence in its potential for growth and profitability. With a market capitalization of around $103.9 million and a trading volume of 122,885 shares, BioLargo is demonstrating its capacity to capture the attention of the investment community. The fluctuation in stock price, ranging from a low of $0.15 to a high of $0.45 over the past year, indicates a growing interest in the company’s solutions for environmental and cleantech challenges.

In conclusion, BioLargo, Inc. is at the forefront of addressing some of the most pressing environmental issues of our time, particularly PFAS contamination in water. Through its AEC technology, the company is not only meeting but exceeding new EPA standards, offering a more sustainable and cost-effective solution for water providers. With its comprehensive approach to tackling PFAS contamination and its promising financial performance, BioLargo is well-positioned to make a significant impact in the cleantech and life sciences sectors.

For more information, visit the company’s website at www.BioLargo.com.

• SOBRsafe CEO Dave Gandini recently communicated the company’s 2023 progress in expanding its line of products as well as its sales outreach and focus for 2024; view the video here
• Last fall, SOBRsafe’s management directed the company’s sales effort toward the behavioral health and justice segments, sectors that already have embedded alcohol monitoring procedures, but need better monitoring and screening solutions
• SOBRsafe provides SOBRsure(TM) and SOBRcheck(TM), next-generation touch-based alcohol detection and monitoring solutions that fit the behavioral health and justice segments “to a tee,” according to Gandini
• As a result of its redirected efforts, the company has secured 16 new accounts in the past three months, compared to three accounts for the whole of 2023

For most of 2023, SOBRsafe (NASDAQ: SOBR), a company that provides next-generation transdermal alcohol detection and monitoring solutions, took a broad approach to marketing its technology, which appeared to have near-universal applicability, according to company Chair and CEO Dave Gandini. The learnings from this initial approach have since informed SOBRsafe’s tighter focus for 2024, which is intended to help the company grow sales and generate cash flow and net income.

“What we discovered with all our outreach in 2023 was that there are businesses and services that already use different alcohol testing technologies, and, in these sectors, that use of testing is mandated. It’s not a want, it’s a need. These sectors already use alcohol detection products as a matter of standard procedure, but are hungry for evolved monitoring and screening solutions,” said Gandini, who was speaking in a recent presentation, a part of the Lytham Spotlight Series (https://ibn.fm/JupAw). “So, what are these markets? Behavioral health (alcohol recovery and mental health) and what we term the ‘justice’ segment.”

Currently, legacy detection methods are used to routinely screen patients in the care of behavioral health facilities, as well as those in outpatient monitoring programs, to establish the presence or absence of alcohol. Based on breath, urine, or blood samples, these methods are considered invasive, unhygienic and degrading. In addition, they are typically analog – they require a staff member to administer the test and write the results down, making them inefficient, time-consuming, and error-prone.

Similarly, SOBRsafe uncovered opportunities within the justice segment. According to Gandini, this segment “relates to basically all things outside of police DUI screening. For example, this segment would include resident testing at halfway houses, or for proof of pre-trial sobriety. There are also employment and insurance mandates where an employee with a previous infraction is only allowed to continue working if they demonstrate sobriety every day.”

Beginning in the fourth quarter of last year, SOBRsafe management directed the company’s sales efforts toward these two segments. Contemporaneously, the company launched SOBRsure(TM), a wearable wristband that utilizes the same SOBRsafe hardware and software platform for ongoing, real-time alcohol monitoring and GPS tracking. SOBRsure(TM) complements the company’s point-of-care alcohol screening product, SOBRcheck (TM), with both products fitting the behavioral health and justice segment to a tee, according to the presentation.

In addition, Gandini also discussed the success of the company’s informed focus, saying, “We’ve secured 16 new accounts in the past three months… vs. just 3 for all of 2023. We believe that this success represents just the beginning of our broad adoption in behavioral health and justice. We believe that success breeds success and that these new relationships will help spark additional and large deals. To fuel this growth, we have a strong team of 4 direct sales professionals and 8 behavioral health field affiliates across key markets.”

SOBRsafe is also working on international expansion as well as licensing and integration. “At the end of January, we announced that we had signed a channel partnership in Australia and New Zealand to target their behavioral health and justice needs. This announcement has driven inbound interest from other countries, with conversations underway,” continued Gandini. In the meantime, SOBRsafe continues to target the more than 46,000 behavioral health facilities across the United States, where its technology could have immediate application.

To watch the presentation, please visit https://ibn.fm/H6B90.

For more information, visit the company’s website at www.SOBRsafe.com.

NOTE TO INVESTORS: The latest news and updates relating to SOBR are available in the company’s newsroom at https://ibn.fm/SOBR

• HealthLynked Corp. is a pioneering healthcare technology company revolutionizing patient care through innovative digital solutions
• Dr. Michael T. Dent, CEO and Chairman, leads the company with a significant history of successful healthcare management and technology development; his prior leadership at NeoGenomics Laboratories, a company with a current market cap of approximately $2 billion, underscores his ability to scale healthcare solutions in competitive markets
• HealthLynked’s recently launched HealthLynked Network is a state-of-the-art, cloud-based platform designed to significantly improve the efficiency and quality of patient care by enabling a seamless exchange of medical information
• The leadership’s deep involvement and commitment are reflected in their continuous innovation and strategic expansions, ensuring alignment with long-term investor interests and enhancing shareholder value

HealthLynked (OTCQB: HLYK) is at the forefront of a transformative movement in healthcare, utilizing its extensive collection of health data to improve care for all. With a commitment to leveraging its advanced technology platforms, HealthLynked employs a sophisticated, cloud-based network that serves as a comprehensive repository for personal health data. This system not only simplifies the management and archiving of medical records but also enables the application of AI to deliver personalized healthcare insights. Through deep analysis of this data, HealthLynked’s AI capabilities help identify the root causes of diseases, tailor healthcare solutions to individual needs, and accelerate medical discoveries.

In addition to these capabilities, HealthLynked provides a user-friendly platform for booking healthcare appointments, similar to how OpenTable operates for restaurant reservations. This feature allows patients to conveniently book appointments with healthcare providers across the country, including options for telemedicine consultations, enhancing accessibility and efficiency in healthcare service delivery.

Strategically headquartered in Naples, Florida, HealthLynked operates through three primary divisions: Health Services, Digital Healthcare, and Medical Distribution. Each division supports the company’s mission to revolutionize patient care and health management. Positioned as a potential leader in healthcare AI, HealthLynked is dedicated to shaping the future of the industry over the next 20 years, driving significant advancements in healthcare accessibility and effectiveness through innovation and technology.

Strategic Initiatives and Operational Highlights

The company’s commitment to enhancing global health is evident in its dual goals: transforming healthcare through advanced technology and creating a patient-centric network that accelerates medical discoveries and the development of disease cures.

HealthLynked’s intellectual property portfolio is robust and strategically developed to enhance healthcare delivery and management. In March 2023, HealthLynked was granted a patent for a groundbreaking healthcare-specific wireless access point, known as the “Patient Access Hub.” This technology significantly improves the efficiency of healthcare practices by enabling real-time monitoring of patient flow within facilities. It intelligently determines patients waiting in exam rooms and calculates wait times, alongside other critical practice metrics. This system not only enhances patient experience by reducing unnecessary wait times but also optimizes resource allocation within healthcare settings.

Additionally, in October 2023, HealthLynked filed a patent application for its advanced AI program, ARI (Augmented Real-time Interface). ARI acts as a virtual doctor for patients, capable of performing medical intake, booking appointments, and providing personalized medical recommendations based on a patient’s medical history. By integrating these tasks, ARI streamlines the healthcare process, reducing the administrative burden on healthcare providers and ensuring that patients receive timely and tailored healthcare advice. This AI-driven interface enhances the accessibility and personalization of healthcare, embodying HealthLynked’s commitment to leveraging technology for better health outcomes. The company recently launched HealthLynked 3.2.0, an advanced version of its application, incorporating telemedicine, AI-driven personal healthcare guidance, and remote patient monitoring – setting a new standard in healthcare technology.

Market Position and Future Outlook

According to Facts and Figures Research, a research and consulting firm, the global market for patient-centric healthcare applications is projected to reach $41.6 billion by 2030, growing at a CAGR of 18.77% from 2022. HealthLynked’s offerings align perfectly with this expansive market opportunity, especially with increasing demands for digital health solutions and data management in healthcare.

HealthLynked’s strategic direction, spearheaded by its seasoned management team, is designed to leverage these market dynamics, enhancing patient engagement and healthcare efficiency on a global scale.

Management Team

Michael T. Dent, M.D., Founder, CEO, and Chairman, brings extensive experience from his foundational role at NeoGenomics and leadership in various healthcare and technology sector companies.

David Rosal, CFO, with previous senior roles at Teradata and McDonald’s Corporation, brings a wealth of expertise in financial and business integration strategies essential for growth and operational efficiency.

Chris Hall, CTO, with a strong background in global technology development from his time at Siemens and several patents to his name, is instrumental in driving the innovation and technological advancement at HealthLynked.

Bill Crupi, Operations Manager, has a proven track record in streamlining operations and enhancing productivity across multiple sectors within the healthcare industry. His expertise is crucial in maintaining the operational excellence that HealthLynked is known for.

Michael Paisan, Director of Investor Relations, leverages his extensive experience in finance and communications to enhance HealthLynked’s relationships with investors and stakeholders, ensuring transparent and effective communication of the company’s value and growth strategy.

Gagan Babber, Manager of Software Development, oversees the HealthLynked development teams based in the U.S. and India. With a robust background in engineering and software development, he plays a critical role in guiding the technological direction of HealthLynked’s products. His expertise in developing scalable, innovative software solutions is essential for driving the company’s technical initiatives forward and ensuring that HealthLynked stays at the forefront of digital healthcare technology.

For more information, visit the company’s website at www.HealthLynked.com.

NOTE TO INVESTORS: The latest news and updates relating to HLYK are available in the company’s newsroom at https://ibn.fm/HLYK

• Copper is expected to play an increasingly important role in powering the world’s transition towards net zero technologies
• The average electric vehicle can contain up to 183lbs of copper, a massive 277% increase relative to internal combustion engine cars
• The surge in copper demand is expected to drive a necessary increase in supply, requiring an additional 9.7 million metric tons (Mt) production per annum by 2031. With a deficit of 114,000 tonnes projected for 2023, the copper supply is anticipated to remain in deficit by the beginning of the next decade with a forecasted shortfall of 6.5 Mt
• Torr Metals is looking to fill that supply imbalance through two ongoing highway-accessible copper-gold porphyry projects within two of Canada’s most prolific copper mining districts
• Recent findings in the company’s Kolos Copper-Gold Project have been extremely promising and suggestive of a significant new copper porphyry discovery, within 30 kilometers of Canada’s largest open pit copper mine at Highland Valley

Global warming has become an undeniable force around the globe, with news of widespread droughts, record temperatures, forest fires, and ravaged agricultural harvests increasing in frequency. In response, global leaders came together during 2021’s COP26 event in Glasgow to propose a global Net Zero initiative, aimed towards achieving a balance between global greenhouse gas (“GHG”) emissions and those being removed from the atmosphere. Whilst a number of countries have since published their own legislation, detailing the measures and timeframes through which they expect to achieve a net zero status, there is a common consensus amongst all – the change will not be easy. Forecasts by the International Energy Agency now suggest that to reach global net zero emissions by 2050, annual clean energy investment around the globe will need to more than triple to approximately $4 trillion per annum by 2030 (https://ibn.fm/rDqO8).

The shift away from fossil fuels and towards renewable energy sources is resulting in a spending surge which is set to directly benefit businesses entrenched within the global renewable energy supply chain; in particular, commodities such as copper – a critical component within green energy technologies – are poised to witness a dramatic uptick in demand.

The average battery electric vehicle (“EV”) today contains approximately 183 pounds of copper per vehicle, a remarkable increase of 277 percent relative to the average copper content of an internal combustion engine-powered car. Metals consultancy Wood Mackenzie has forecast the share of global copper demand coming from ‘green’ sectors, including renewables and EVs to double over the next decade, from approximately 8 percent of demand today to upwards of 16 percent. In Wood Mackenzie’s base case forecast, world copper consumption is set to rise by about 24 percent between 2023 and 2033, reaching about 32 million tons a year (https://ibn.fm/nhBdG).

Nevertheless, the consultancy has forecast that the required increase in global copper supply is yet to materialize, with Wood Mackenzie estimating that a further 9.7Mt of copper supply over the next decade would have to come online to help fulfil the world’s ambitions to limit global warming to 1.5 degrees centigrade as per the statutes of the Paris Agreement. In turn, a failure to drive this increased supply could lead to a growing market deficit, which could underpin a copper price rally to upwards of US$11,000/t (about US$5.00/lb) within a five-year period (https://ibn.fm/zOyta).

Vancouver-based Torr Metals (TSX.V: TMET), a mineral exploration company focused on the identification, acquisition and advancement of mineral properties has sought to address this burgeoning supply-demand imbalance, through its holdings of over 1,000 square kilometers of gold and copper projects, spread across an array of premier low-cost mining jurisdictions, some of which have resulted in promising findings to date – the Kolos Project chief amongst these.

In September 2023, Torr acquired 100% ownership of the district-scale Kolos Copper-Gold Project, nestled within British Columbia’s prime copper-producing belt. Torr Metals recently carried out the first-ever regional sampling program, totaling over 3,300 soil samples spread across a range of 48 square kilometers that has never been drill tested. The analysis unearthed the potential presence of five large zones with high levels of copper (ranging from 200 parts per million to as high as 1,175ppm), suggestive of a substantial clustered copper porphyry deposit boasting strong geological similarities to nearby porphyry deposits (https://ibn.fm/3Cu95). Whilst Torr Metals is still awaiting final results from ongoing rock grab assays and geophysical surveys, as well as the granting of their drill permits, initial findings have placed it in strong stead to capitalize on growing global demand for the red metal going forward.

For more information, visit the company’s website at www.TorrMetals.com.

NOTE TO INVESTORS: The latest news and updates relating to TMET are available in the company’s newsroom at https://ibn.fm/TMET

• The European Union recently signed its inaugural ‘European Solar Charter’, aimed at driving the growth of the continent’s solar industry
• Turbo Energy has emerged as one of the leading companies within the European solar supply chain, with its array of residential and industrial energy storage solutions
• The company recently revealed that its range of ‘GoSolar’ residential solar energy solutions would be distributed by El Corte Ingles, Europe’s largest department store chain
• Turbo Energy also announced its FY2023 financial results, revealing FY23 revenues of USD 14.54 million

The European Commission and representatives of the continent’s solar energy parts manufacturers came together on April 15th to sign a charter, aimed towards achieving resilient within the European Union’s solar value chain and help meet the bloc’s renewable energy targets (https://ibn.fm/iVywL). A key element of the European Solar Charter signed by 23 of the 27 EUR countries, signaled a commitment from the signatory governments to realize the pending Net-Zero Industry Act (“NZIA”), legislation which will aim to ensure that the EU will have the manufacturing capacity for renewable technologies, including photovoltaics, nears 40 percent of annual deployment needs by 2030.

The European Union sourced 23 percent of its energy needs from renewable sources in 2022, largely driven by solar energy; nevertheless, that proportion seems likely to increase dramatically in upcoming years. The EU has set a new target of sourcing 42.5 percent of its energy needs from renewable sources for 2030, an ambition which will require a double of the rate of renewables deployment seen over the past decade alongside an ongoing transformation of the European energy system (https://ibn.fm/DpIDT).

Turbo Energy (NASDAQ: TURB), a designer, developer and manufacturer of photovoltaic energy generation, management, and storage equipment is one of the companies striving to help meet this objective through its range of power storage solutions. The company’s GoSolar range, an array of lightweight and portable solar energy solutions, seeks to provide consumers with cost-effective options for reducing electric bills and minimize their carbon footprint (https://ibn.fm/GZv2e). Designed for easy installation and compatibility with most household outlets, GoSolar will provide households with an accessible route towards renewable energy adoption.

Turbo Energy has now revealed that its GoSolar range of residential solar solutions will be distributed by El Corte Ingles S.A, Europe’s largest department store group and the third largest worldwide. The partnership between Turbo Energy and Corte Ingles will further burnish El Corte Ingles’ commitment to innovation and sustainability, extending the retail company’s wide range of offerings.

Mariano Soria, CEO of Turbo Energy, expressed enthusiasm about the collaboration, stating, “We are very excited that El Corte Inglés S.A., the third largest department store group in the world, will be selling our GoSolar product. This development, we believe, will contribute to the sustainable reduction of energy costs for thousands of homes.”

Collaborations such as the recently revealed distribution agreement with El Corte Ingles as well as the previously announced partnership with Solar360, the energy division of Movistar have played a growing part in the expansion of Turbo Energy’s retail footprint, with Turbo Energy announcing full year 2023 revenues of USD 14.54 million for the recently concluded financial year (https://ibn.fm/gYrfM).

For more information, visit the company’s website at www.Turbo-e.com.

NOTE TO INVESTORS: The latest news and updates relating to TURB are available in the company’s newsroom at https://ibn.fm/TURB